Eight months of HeartMate II device support without drug therapy
Thromboembolic complication rates of 20%–30% were initially a major limitation to the widespread use of left ventricular assist devices. The success of the HeartMate (Thoratec, Corp., Pleasanton, CA, USA) device has been partly due to the reduced incidence of thromboembolic events, although anticoag...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of the Practice of Cardiovascular Sciences |
| Subjects: | |
| Online Access: | http://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=2;spage=122;epage=124;aulast=Krishan |